#cannabisaficionado

Health

Boots Launches SureLeaf as Medical Cannabis Meets Mainstream Pharmacy

Boots has launched a private medical cannabis service for eligible adults. Specialist assessment and ongoing reviews remain central to access.

Published

on

A stethoscope resting on an open notebook on a wooden desk
Advertisement Back2Grow Advertisement

Boots Online Doctor launched SureLeaf on November 16, bringing a specialist medical cannabis service under one of Britain’s best-known pharmacy names. The private service is aimed at eligible adults with chronic pain, generalised anxiety disorder or insomnia whose conventional treatments have not provided adequate symptom relief. Access depends on clinical assessment; the announcement does not make cannabis an over-the-counter medicine.

For patients, the immediate question is what the familiar Boots name changes. It creates another route to a specialist consultation, rather than a promise that a particular diagnosis will result in a prescription. The larger question remains whether treatment delivers meaningful, sustained benefits for an individual patient, with acceptable risks and appropriate follow-up.

Who can use the new service?

In its launch announcement, Boots sets the minimum age at 25. An online assessment is reviewed before a video appointment with a consultant in the relevant specialty who appears on the General Medical Council Specialist Register. A proposed prescription then goes to a multidisciplinary team that includes a second, independent consultant.

Boots says monitoring includes a review after 28 days and further reviews at least every three months. Questionnaires will track areas including quality of life, pain, anxiety, sleep and mood. Those details matter because an initial prescription is only one stage of care. Reviewing whether someone is actually doing better is part of the service being offered.

Patients considering an appointment should distinguish eligibility from suitability. Meeting an age threshold or having a listed condition gets someone to the assessment question; it cannot settle the prescribing decision. A useful consultation should also make clear what outcome is being sought, how progress will be assessed and what would prompt a change or an end to treatment.

A private route alongside limited NHS access

The NHS explanation of medical cannabis describes a much narrower setting for routine access in England, including certain severe epilepsies, chemotherapy-related sickness and multiple-sclerosis spasticity. It says evidence for pain relief has not been strong enough to support a general recommendation. A private service launch does not itself change those NHS criteria.

The NHS also distinguishes prescribed medicines from cannabis oils and CBD products sold through shops or online. Products marketed with similar language can differ in composition, quality and intended use. A bottle on a retail shelf therefore cannot be treated as the equivalent of a specialist prescription, and the presence of CBD on a label does not establish that it will address a patient’s condition.

For readers comparing routes, the practical questions include the full cost of consultations, medication and repeat reviews, as well as what happens if treatment is unsuitable. Those questions deserve answers before a financial commitment. The company’s announcement is evidence that a service exists, not an independent comparison of its cost or quality against other clinics.

Why the evidence debate continues

The Faculty of Pain Medicine’s 2026 patient information leaflet takes a cautious position on long-term pain. It says there is insufficient evidence about effectiveness and safety to support routine use, and calls for more research. Its discussion concerns pain; it should not be stretched into a finding about every condition or every cannabis-based medicine.

That distinction prevents two misleading readings of Monday’s launch. Commercial availability is not proof that clinical uncertainty has disappeared. Equally, uncertainty about chronic pain does not mean that all medicines containing cannabinoids have identical evidence or uses. The question needs to be tied to a specific product, condition and patient outcome.

The leaflet’s emphasis on research also helps explain why patient experience and controlled evidence answer different questions. Someone’s reported improvement can be important to their care without establishing that the medicine caused the improvement or will help other people. Changes in other treatments, symptoms and circumstances must also be considered when interpreting outcomes.

What to watch after launch

Boots says it is exploring a research collaboration with the University of Nottingham concerning chronic-pain outcomes, prescribing practice and patient experience. That is an intention under discussion, not a completed study or a published result. Any eventual research will need to explain who was included, how outcomes were measured and what limitations affect its conclusions.

Our coverage of a planned medical cannabis outcomes registry explains why following patients over time matters. A proposed data collection effort and a completed analysis are different stages; neither a service launch nor a research announcement should be presented as findings.

SureLeaf’s arrival is a notable distribution and access development. The more meaningful test will come after the launch publicity: whether assessment, monitoring and transparent reporting give patients a clear account of benefits, adverse effects and reasons to continue or stop care.

Illustrative medical still life; not a Boots clinic or a cannabis prescription. Photo: Tima Miroshnichenko / Pexels.

Health

Iowa Medical Cannabis Board Backs Removing Patient Sales Tax

Iowa’s advisory board has backed seven medical cannabis recommendations, including ending patient sales tax. Legislative action would still be needed.

Published

on

Iowa State Capitol in Des Moines, with its gold central dome, smaller domes and green lawn

Iowa’s Medical Cannabidiol Board has backed removing sales tax from medical cannabis purchases, placing patient cost among its recommendations for the state’s next legislative discussion. The board voted November 6; the recommendation became the subject of new reporting November 13.

Patients should not read the vote as a tax exemption already available at the dispensary. The board advises policymakers. Its recommendation still needs to move through the process that changes Iowa law before it can alter what a customer owes.

The Marijuana Herald reported that Iowa Health and Human Services spokeswoman Danielle Sample confirmed seven unanimously approved recommendations in an email to that publication. Those proposals range from tax treatment and terminology to prescribing oversight and the products the program permits.

Patient cost moves onto the policy agenda

Removing sales tax would address one component of the amount a patient pays. It would not, by itself, set a product’s base price, lower the program’s registration fee or guarantee a particular amount of household savings.

That distinction is especially relevant in a medical program where participation has its own administrative costs. The state’s patient guidance currently lists a $100 application fee, with a $25 fee for eligible applicants. Cards expire after one year. Those are separate requirements from sales tax on purchases.

A patient comparing the proposal with today’s expenses therefore has several different numbers to consider: registration, the price of the product and tax. A recommendation about one should not be presented as a reform of all three.

The board’s November meeting presentation also put participation in context. It showed 17,974 active patients in January and 17,698 in September, a decline of about 1.5 percent. Those figures describe enrollment at two points; they do not establish why people joined, left or bought less cannabis.

Seven recommendations, with different consequences

The November 6 presentation, prepared by HHS cannabis regulation bureau chief Owen Parker and available in a copy hosted by an Iowa advocacy organization, lists the seven recommendations. Alongside eliminating patient sales tax, the board backed renaming Chapter 124E the Medical Cannabis Act.

The terminology proposal would align the law’s name more directly with the program’s subject. Renaming a statute, however, is distinct from expanding the products available under it. The board also reaffirmed its opposition to raw flower, so the package should not be mistaken for a recommendation to create a flower market.

Two further recommendations address tax equality for licensed businesses and a federal exemption related to potential rescheduling. Those concern the industry’s legal and financial environment. They are separate from the proposed exemption at the patient checkout, even though all involve the economics of medical cannabis.

The remaining recommendations concern prescribers’ access to patient purchase histories and oversight of telemedicine. Access to records and remote care can affect how a program operates, but the board’s vote does not itself supply a new prescribing procedure for patients to follow today.

What Iowa currently allows

The state’s patient guidance describes a program built around authorized preparations rather than raw cannabis flower. It lists vaporizable cartridges and concentrates, oral and sublingual forms such as tablets and tinctures, and topical preparations. It identifies raw flower for combustion or smoking and certain edible products as prohibited.

That existing framework helps explain why the board’s flower position matters. A tax recommendation can be significant for patients while leaving the range of authorized products unchanged. A lower checkout burden and broader product choice are different policy decisions.

Participation also requires certification and a state application. HHS identifies several eligible practitioner types, including physicians, physician assistants and advanced registered nurse practitioners. The recommendation package does not replace those current entry requirements or create automatic eligibility for anyone who wants to buy cannabis.

Where the proposal goes from here

HHS describes the board’s role as advisory and requires an annual report by January 1. Its membership includes eight physicians and one law enforcement representative. The department’s calendar independently confirms the November 6 meeting date.

The next meaningful development will be a legislative proposal or another formal action that translates a recommendation into enforceable language. Until then, the accurate description is that the board supports removing patient sales tax, rather than that Iowa has removed it.

For readers following our coverage of state cannabis rulemaking, the distinction is familiar: an official vote can move policy forward without opening a new service or changing a consumer’s rights immediately. Iowa patients have a concrete cost proposal to watch, with its practical effect still dependent on what lawmakers do next.

Stock view of the Iowa State Capitol in Des Moines; not the November 6 board meeting. Photo: Pixabay / Pexels.

Continue Reading

Health

Senate Funding Proposal Renews the Call to Study Cannabis and Opioid Use Among Veterans

New Senate appropriations language asks for more evidence on medical cannabis and opioid use among veterans, while important research questions remain unresolved.

Published

on

The United States Capitol dome and an American flag against a blue sky

A newly released Senate funding proposal puts veterans’ medical cannabis research back on the federal agenda. The recommendation asks the Department of Veterans Affairs to consider clinical research on medical marijuana and to examine the relationship between state-approved programs, veterans’ access to them and reductions in opioid use and abuse.

The cannabis connection is direct, but the distinction between a research request and a medical conclusion matters. The language does not establish that cannabis reduces opioid use, announce results from a new trial or itself change an individual veteran’s treatment. It identifies questions the committee wants studied.

The Senate Appropriations Committee released two fiscal year 2027 funding bills and accompanying materials on November 10. Tom Angell highlighted the cannabis provisions for Marijuana Moment on November 11. The relevant VA language appears under medical and prosthetic research in the Military Construction and Veterans Affairs explanatory statement.

What the recommendation actually asks

The statement encourages clinical cannabis research and recommends a study connecting three subjects: state medical marijuana treatment programs, veterans’ access to those programs and opioid outcomes. Those are related questions, but they are not interchangeable. Being legally able to enter a program does not show whether a patient enters it, what product is used or what happens afterward.

The document is part of the appropriations process. Its publication should not be described as Congress enacting a new cannabis benefit or VA launching a particular study. Further decisions would be needed to turn a research recommendation into a defined project with investigators, a protocol and a timetable.

The distinction also applies to the money discussed nearby. The explanatory statement recommends $922 million for the overall Medical and Prosthetic Research account, alongside an estimated $57 million from the Toxic Exposures Fund. Those broad research figures are not a cannabis-specific allocation, and the cannabis paragraph should not be read as assigning that entire budget to marijuana research.

Why the opioid question needs careful study

One useful piece of background is a 2021 systematic review led by Atefeh Noori in BMJ Open. It evaluated studies of adding medical cannabis or cannabinoids to prescription opioids for chronic pain. The review included five randomized trials and twelve observational studies and concluded that opioid-sparing effects remained uncertain because the evidence was of very low certainty.

An important design limitation was that the randomized trials instructed participants to maintain their opioid dose. That makes them difficult evidence for answering whether patients could reduce that dose. Observational findings can raise useful questions, but they do not automatically establish that cannabis caused a change.

A separate 2024 systematic review and meta-analysis examined nonmedical opioid use among people receiving medications for opioid use disorder. Across ten longitudinal studies involving 8,367 participants, it found no significant association between cannabis use and nonmedical opioid use. The authors did not interpret that finding as proof that cannabis reduces such use.

These reviews concern different populations and outcomes. Chronic pain treatment, prescribed opioid dose and nonmedical opioid use during addiction treatment should not be collapsed into a single claim. Neither review is a new November 2026 finding or a substitute for research designed around veterans’ particular circumstances.

Access and evidence are different policy tracks

The new Senate language also sits alongside state efforts to change access. Our reporting on Massachusetts’ proposed route to medical cannabis for veterans addresses that separate policy question. Expanding or simplifying access and measuring clinical outcomes can proceed as distinct debates, with different evidence needed for each.

For patients, the practical question is what their own care team and applicable program rules allow. A committee’s research recommendation does not provide a dosing plan or a reason to stop prescribed medication. The document is most useful as a signal about federal research priorities, rather than as personalized medical guidance.

Researchers would also need to report who was included and who was missing. Results from one age group, diagnosis or pattern of product use may not describe another, especially when products and treatment settings differ.

What would make the next update meaningful

The next developments to watch are concrete: whether the language survives the funding process, whether VA identifies a study and whether its methods distinguish program access from actual cannabis exposure. Clear outcome measures and follow-up periods would help readers understand what any eventual result can support.

On Veterans Day, the proposal gives cannabis research renewed visibility. Its strongest promise is the possibility of better answers. Until those answers exist, a request to investigate the relationship between cannabis and opioids should remain exactly that—a research question, rather than a finding announced in advance.

Stock photograph of the U.S. Capitol; not a photograph of the funding proposal’s release. Photo: Ben Kelsey / Unsplash.

Continue Reading

Health

Washington’s Medical Cannabis Hearing Puts Product Labels in Focus

Washington’s medical cannabis proposal addresses labeling, testing and product classifications. A November 10 hearing precedes any final rule.

Published

on

Amber glass bottles and a pipette on a light surface

Washington’s proposed medical cannabis product rules reach a public hearing today, bringing labeling, testing and product classifications into the same discussion. For patients and retailers, the practical question is how clearly a product’s contents and supporting test information can be identified.

The Department of Health’s formal proposal, WSR 26-20-094, lists a November 10 virtual hearing at 11 a.m. Washington time, or noon in Phoenix. It identifies November 17 as the intended adoption date. A hearing and an intended date do not make the proposed language an effective rule.

More than a vocabulary change

The proposal would revise chapter 246-70 of the Washington Administrative Code. Its stated scope includes medical cannabis classifications, certain THC and CBD thresholds, labeling and quality-assurance testing. It also replaces older marijuana terminology with cannabis and proposes a section collecting statutory tax-exemption references.

Those subjects affect different parts of a patient’s encounter with a product. Classification describes the relevant category; testing concerns the evidence behind the product; labeling concerns what information reaches the person choosing it. Treating the entire package as a simple terminology update would overlook its operational implications.

Conversely, the word medical in a regulatory classification should not be confused with a guarantee that a particular product treats a particular condition. The proposal’s product-information approach is about standards and disclosure, not a substitute for evaluating an individual health claim.

A clearer route from label to test information

The draft would require a label link, web address or QR code leading to the certificate of analysis and product-specific pesticide information. It also addresses harvest or production dates and certain terpene information. A medically endorsed retailer would have to provide a hard copy of the analysis when requested by a patient or designated provider.

For a shopper, these provisions concern access as much as data. Information that exists somewhere in a supply chain is less useful if it cannot be matched to the product in hand. A readable link and an available paper copy offer different ways to reach the underlying record.

A certificate of analysis still needs context. Readers should distinguish a laboratory result for a product from a broad promise about how that product will affect an individual. Testing information can help establish what was measured without answering every question about suitability or personal response.

What retailers and producers would need to examine

If adopted, revised labeling requirements would prompt businesses to compare their current labels and information systems with the final text. The useful work starts with identifying the actual fields involved, who supplies them and how they remain connected to the correct product.

A QR code alone does not make a disclosure useful. Its destination needs to work, be understandable and correspond to what the label promises. That is an implementation question readers can recognize without assuming that a proposed technical requirement has already taken effect.

The proposal also preserves a distinction between official medical-grade identifiers and promotional imagery. Its labeling section restricts specific therapeutic claims and certain pharmaceutical-style presentation. Clear compliance information and medical marketing are not interchangeable, even when both appear on packaging.

Tax references need the same care

The proposed new tax section is described as clarifying existing statutory exemptions in one place. It should not be summarized as an announcement that every cannabis purchase will become tax-free. A patient’s eligibility, the product and the retail setting remain separate matters to check against the applicable provisions.

For readers comparing a shelf price with a checkout total, the useful question is which specific exemption applies to which transaction. A general reference to medical cannabis cannot supply that answer by itself. The proposal’s organizational purpose does not remove the need to read the relevant conditions.

Our report on Oregon’s cannabis health update similarly focused on asking precise product questions. Washington’s rulemaking approaches that issue through a different tool: proposed requirements for product standards and the information available to patients.

Follow the final rule after the hearing

The notice accepts written comments through November 10 at 11:59 p.m. and provides submission instructions in the official filing. Anyone checking the process should confirm the latest agency notice, especially if an event or deadline has already passed when reading this story.

The next meaningful checkpoint is the adopted text and its effective date, if the department proceeds. Until then, the accurate description is a medical cannabis standards proposal with a scheduled hearing. That preserves room for public input and possible changes, while giving patients and businesses a concrete set of issues to follow.

A useful label question for that next stage is simple: can a patient reach the relevant product record without guessing which batch or item it concerns? The answer depends on implementation as well as the wording adopted.

Illustrative packaging stock photo; not identified as cannabis or a Washington medical product. Photo: Nataliya Melnychuk / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.